Aeterna Zentaris (NASDAQ:AEZS) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Down 1.3 %

NASDAQ AEZS opened at $1.95 on Friday. The stock has a market capitalization of $9.48 million, a PE ratio of -0.57 and a beta of 1.57. Aeterna Zentaris has a 52 week low of $1.36 and a 52 week high of $3.38. The firm has a 50 day moving average of $1.95 and a two-hundred day moving average of $1.90.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.